FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP
CIAILIVILIAI	OI OIIAIGES	III DEIIEI IOIAE	CAMINETOLIN

OMB APPR	OVAL				
OMB Number:	3235-0287				
Estimated average bure	den				
hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Hineline Lawrence J.						2. Issuer Name and Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [ITCI]									ationship of Reporting all applicable) Director Officer (give title		g Pers	g Person(s) to Issuer 10% Owner Other (specify	
	RA-CELLI	(First) (Middle) CELLULAR THERAPIES, INC. TH STREET				3. Date of Earliest Transaction (Month/Day/Year) 09/21/2022									below) SVP of Finance CFO				
(Street) NEW YO		tate)	10016 (Zip)		-	4. If Amendment, Date of Original Filed (Month/Day/Year)						Li	ne) X F						
		Tak	ole I - No			_			-	l, Dis	sposed o								
D I Tille of Goodinity (mounty)			Date			2A. Deemed Execution Date, if any (Month/Day/Year)		Transa Code (Transaction Code (Instr.		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4		4 and 5) Securi Benefi Owned		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Tr	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common Stock 09/2				09/21	/2022	2022		М		65,164	A	\$15.4	315.47		65,164		D		
Common Stock 09.				09/21	/2022	2022			S ⁽¹⁾		31,861	D	\$45.8	33,303		,303		D	
Common	Stock			09/21	/2022	2			S ⁽¹⁾		33,303	D	\$45.3	9(3)	0 D				
		•	Table II						,		osed of,			y Owr	ed				
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date,		4. Transacti Code (Ins 8)		5. Number on of		6. Date Exercisable a Expiration Date (Month/Day/Year)		sable and	d 7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	Owner Form Direct or Inc (I) (In:	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares						
Stock Option	\$15.47	09/21/2022			M			65,164	(4)		01/03/2028	Common	65,164	\$0	.00	0		D	

Explanation of Responses:

- 1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$45.58 to \$46.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$45.01 to \$45.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- 4. All shares underlying this option have vested.

Remarks:

buy)

/s/ Lawrence J. Hineline

09/23/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.